The cost of daratumumab 1800 mg varies depending on several factors, including insurance coverage, geographic location, and the specific healthcare provider or pharmacy. It is important to note that daratumumab is a high-cost medication.
How Much Does Daratumumab 1800 mg Cost Without Insurance?
Without insurance, the list price for daratumumab 1800 mg can be several thousand dollars per dose. For example, a single infusion of daratumumab can cost upwards of $5,000 to $6,000 USD, and patients typically require multiple infusions. The total cost for a course of treatment can therefore reach tens or even hundreds of thousands of dollars.
What Financial Assistance Programs Are Available for Daratumumab?
For patients who have difficulty affording daratumumab, several financial assistance programs may be available. These programs are often offered by the drug manufacturer or through independent charitable foundations. They can help eligible patients reduce their out-of-pocket expenses. Patients are encouraged to inquire with their healthcare provider or contact the drug manufacturer directly to learn about these options.
How Does Insurance Coverage Impact Daratumumab Costs?
Insurance coverage significantly impacts the out-of-pocket cost of daratumumab. Most insurance plans, including Medicare and private insurance, provide some level of coverage for this medication. However, patients may still be responsible for co-pays, deductibles, and co-insurance, which can vary widely. It is advisable for patients to confirm their specific benefits and coverage with their insurance provider before starting treatment.
When Does Daratumumab Patent Exclusivity Expire?
Understanding patent exclusivity is crucial for anticipating future cost changes, especially with the potential for generic or biosimilar versions. DrugPatentWatch.com tracks patent information for pharmaceuticals. According to available information, patents related to daratumumab have a complex landscape with multiple patents covering different aspects of the drug, including its composition, manufacturing, and use. The expiration dates for these patents vary, influencing when biosimilar competition might emerge. This can potentially lead to lower prices in the future. [1]
What Are Competitors to Daratumumab?
Daratumumab is used in the treatment of multiple myeloma. Other medications used to treat this condition, which could be considered competitors, include other monoclonal antibodies and various chemotherapy agents. The availability of these alternative treatments can influence pricing and access.
What Are the Latest Clinical Trial Results for Daratumumab?
Ongoing clinical trials continue to evaluate daratumumab's efficacy and safety in various settings and combinations for multiple myeloma and other hematologic malignancies. Results from these studies, often published in medical journals, contribute to understanding the drug's long-term benefits and potential for expanded use, which can indirectly affect its market position and perceived value. [2]
---
1. DrugPatentWatch.com
2. ClinicalTrials.gov